Haemonetics Corporation

HAE · Medical Instruments · $4.9B
Powering up
HAE
$108.40
▲ +0.74%
09/18 O 108.95 H 110.45 L 107.60 C 108.40 ▲ +0.74%
Vol 1.3M RS 94
RS rating94
Now vs pivot (%)+32.21%
Tightening (ATR ratio)1.37×
Volume dry-up1.78×
Up/down volume, net0.19
From 52-week high2%
squatcoolingclimbing
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 6.2 weeks and fell 12% from its ceiling at its deepest. The pivot is $81.99, and the stock closed 32.2% above that pivot. Its relative strength rating is 94.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?Zacks Investment Research · 1 day agoGEHC vs. HAE: Which Stock Is the Better Value Option?Zacks Investment Research · 2026-08-31

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Haemonetics Corporation (HAE) — The Tape